Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 19/20 | 0.68 |
| ▸ | TLR8 | Q9NR97 | 8/20 | 0.56 |
| ▸ | PDE4A | P27815 | 1/20 | 0.53 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.53 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.53 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.53 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24539487 | 0.90 | TLR7 (0.58) | TLR7TLR8PDE4APDE4BPDE4C | |
| SCHEMBL24539495 | 0.85 | TLR7 (0.51) | TLR7TLR8PDE4APDE4BPDE4C | |
| SCHEMBL27197267 | 0.85 | TLR7 (0.54) | TLR7TLR8PDE4APDE4BPDE4C | |
| SCHEMBL24539596 | 0.85 | TLR7 (0.56) | TLR7TLR8PDE4APDE4BPDE4C | |
| SCHEMBL24539651 | 0.85 | TLR7 (0.50) | TLR7TLR8PDE4APDE4BPDE4C | |
| SCHEMBL24539646 | 0.84 | TLR7 (0.58) | TLR7TLR8PDE4APDE4BPDE4C | |
| SCHEMBL24539640 | 0.82 | TLR7 (0.55) | TLR7TLR8PDE4APDE4BPDE4C | |
| SCHEMBL24539599 | 0.82 | TLR7 (0.46) | TLR7TLR8PDE4APDE4BPDE4C | |
| SCHEMBL24539889 | 0.82 | TLR7 (0.54) | TLR7TLR8PDE4APDE4BPDE4C | |
| SCHEMBL24538684 | 0.81 | TLR7 (1.00) | TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124484-A1 | IMIDAZOTHIENOPYRIDINE COMPOUNDS AND METHODS OF USE | ZYMEWORKS BC INC (CA) | 2024-04-18 | — | — | US | disclosed |
| WO-2022126263-A1 | IMIDAZOTHIENOPYRIDINE COMPOUNDS AND METHODS OF USE | ZYMEWORKS INC. (CA) | 2022-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124484-A1 | IMIDAZOTHIENOPYRIDINE COMPOUNDS AND METHODS OF USE | DHFR, RARS2, DPYD | TLR7 1139/4885TLR8 3109/4885PDE4A 2894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.